The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an oral medicine that selectively targets the interleukin-23 (IL-23) receptor for adults with plaque psoriasis — the first oral agent in this mechanistic class to reach this regulatory stage in the European Union.

The recommendation, announced by the EMA, opens a path toward European Commission marketing authorisation for an oral therapy acting at the same receptor that injectable IL-23 p19 inhibitors have blocked at the cytokine level for the past decade.

What does the opinion actually cover?

A positive opinion represents the CHMP's endorsement after reviewing the sponsor's complete dossier — chemistry, manufacturing, preclinical and clinical data — and judging the benefit-risk profile favourable for the proposed indication. The opinion now transmits to the European Commission, which typically issues a binding marketing authorisation decision consistent with the committee's recommendation within roughly two months.

Once authorisation is in force, the medicine can be prescribed across all EU member states. National pricing negotiations, health technology assessments and reimbursement decisions then determine how quickly patients gain access in each market — a step that typically delays real-world availability by additional months after the Commission decision.

Why does IL-23 receptor targeting matter?

The IL-23/IL-17 axis drives the keratinocyte hyperproliferation and cutaneous inflammation that define plaque psoriasis. Injectable biologics blocking IL-23 p19 — including guselkumab, risankizumab and tildrakizumab — have set high efficacy bars measured by PASI 90 and PASI 100 responder rates in phase 3 registration trials. An oral agent acting directly at the IL-23 receptor on T cells represents a pharmacologically distinct route to the same pathway.

For dermatologists, this matters because oral systemic options for moderate-to-severe plaque psoriasis have, until now, remained limited to small molecules acting on different inflammatory nodes: methotrexate and ciclosporin broadly, apremilast at phosphodiesterase-4 and the newer tyrosine kinase-2 inhibitors. An oral IL-23 receptor-targeted agent would bring biologic-class mechanistic specificity into a pill, with potential utility for patients who decline or discontinue injectable biologics.

What changes for clinical practice?

The recommendation does not yet authorise prescription. Until the European Commission acts, the oral agent remains an investigational product across the EU, even as the regulatory door opens toward approval. Prescribers should expect:

• No change in current treatment algorithms until Commission authorisation is in force
• Reimbursement and pricing negotiations at the national level to follow authorisation
• Full prescribing information, including contraindications and the studied patient population, to be defined in the eventual summary of product characteristics

The EMA's announcement, as published in the materials reviewed, did not contain direct quotations from sponsor leadership or principal investigators. Detailed efficacy and safety data — including PASI responder rates, the specific comparators used in registration trials and any safety signals flagged by the committee — will surface in the public assessment report issued around the time of the Commission decision.

What comes next?

The European Commission review now proceeds from the CHMP opinion, and decisions historically follow committee recommendations with rare exceptions. After EU authorisation, the sponsor can pursue parallel filings with the US Food and Drug Administration and other regulators, building a global dossier around the same oral molecule.

The headline finding stands: an oral, IL-23 receptor-targeted therapy has cleared the EMA's scientific hurdle for plaque psoriasis. Whether that translates into a meaningful shift in dermatology practice — or remains a niche addition to the systemic armamentarium — depends on the trial data the sponsor now publishes and the reimbursement terms national authorities eventually negotiate.